Enhancing Europe's Pharma and Biotech Competitiveness and Open Strategic Autonomy
Enhancing Europe's Pharma and Biotech Competitiveness and Open Strategic Autonomy
Brought to you by BritCham and Novartis
Healthcare, Pharma and Biotech: the pursuit of coherence in the age of competitiveness.
Join us for our panel discussion on ‘Enhancing Europe’s Pharma and Biotech Competitiveness and Open Strategic Autonomy’ on 2 October 2024.
Brought to you by:
Our Special Guests
Our speaker lineup includes a number of key policy makers and influential voices from the public and private sectors.
Ms Kristin Schreiber, Director for Chemicals, Health, Retail and Agrifood at the European Commission's DG GROW, plays an active role in the Healthcare sector and will participate in the conversation, along with a number of other speakers to be confirmed. In addition, we will welcome speakers with a commercial perspective on the dynamic healthcare ecosystem, including Claire Skentelbery, Director General at Europabio, Kristin Thompson, Investment Director at Merieux Private Equity Venture Capital expert, and Wojciech Nowak, Senior Director of Global Governmental & Public Affairs at Novartis.
Why we’re co-hosting this:
- Global leadership in pharma and biotech - Determining the priorities of the next Parliament and Commission in supporting the competitiveness and open strategic autonomy of the European biotech sector.
- Biotech as a critical technology - Recognition of Biotech and Biomanufacturing as a critical sector.
- Impact of the GPL on Europe’s Innovation Ecosystem - The General Pharmaceutical Legislation (GPL) is a once in a generation opportunity to update the regulatory framework, optimising conditions for R&D, and improving patients access to medicines across Europe.
- Charles River Associates report - Ensuring a reliable IP system and adequate funding mechanisms for biotech SMEs will be crucial for the European healthcare ecosystem and its competitiveness.
Background
Mario Draghi's upcoming report on European competitiveness marks a pivotal moment for strategic realignment. The Charles River Associates report warns that proposed GPL changes could introduce greater uncertainty for biotech companies, particularly affecting SMEs essential for discovering new treatments and technologies. In response, the European Commission has initiated several measures, such as the "EU Biotech Hub" and a potential "EU Biotech Act". Yet the urgency for a coherent strategy to ensure Europe's strategic autonomy and competitiveness remains.
Event Details
- Location: Renaissance Brussels Hotel
-
Rue du Parnasse 19, 1050 Bruxelles
-
Rue du Parnasse 19, 1050 Bruxelles
- Date: Wednesday 2 October
- Time: 17:00-19:30
- Format:
- Panel discussion and Q&A
- Networking cocktail
If you have any questions or would like to join online, please contact lauren.dishman@britcham.eu.